Remote Access Only

Announcement: Due to ongoing concerns over COVID-19 we have now made this conference a virtual event. All speakers, attendees and sponsors will be able to access the full conference and its materials and will be able to log on remotely via the internet. Please contact a member of the SAE Media Group Team for more information customerservices@SAE Media Group-online.co.uk 


As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.

This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.

It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.


ACS Dobfar SpA; Aelin Therapeutics; Akthelia Pharmaceuticals; AMR Centre; Bioharmony Therapeutics; BioVersys AG; Blueberry Therapeutics Ltd; Case Western Reserve University; Centauri Therapeutics; Charles River; Chemical Biology Ventures; Destiny Pharma; Drug Discovery Today; Evotec (UK) Ltd; Evotec UK Ltd; F2G Ltd; Fairy Gut Mother; Genentech; GSK; Helperby; HPRA; King Abdulaziz University; LifeArc; Meiji Seika Pharma Co. Ltd.; Meiji Seika Pharma Co., Ltd.; Morton Findlay Associates Ltd; MycoBiologics at University of Aberdeen; Nektr Technologies; Oxford University; Phico Therapeutics; PSI CRO AG; Russell Publishing Ltd; SCYNEXIS Inc; Therapeutics; TranScrip Partners; University of Birmingham; University Of Liverpool; University of North Texas Health Science Center; Walter Reed Army Institute of Research; Wellcome Trust; WHO; Wollongong Hospital;

Conference programme

9:00 Chairman's Opening Remarks

Yuri Gleba

Yuri Gleba, CEO, Nomad Bioscience GMBH
View Bio

9:10 Exploring new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins

Yuri Gleba

Yuri Gleba, CEO, Nomad Bioscience GMBH
View Bio

• Origins of non-antibiotic antibacterial proteins – a brief history
• A brief summary of the efficacy and potency of bacteriocins
• Methods and approach to bacteriocin expression – plant hosts
• Key commercialisation aspects, challenges and product candidates

9:50 Development of non-traditional agents and alternatives to antibiotics

Peter Warn

Peter Warn, SVP Anti-infective Discovery, Evotec Inc

• Neutralising virulence effectors
• CAL02: agent chemistry and activity
• Showcasing the results of CAL02 randomised, double-blind, multicentre, placebo-controlled trial
• Exploring the current regulatory landscape around neutralisation of virulence factors and beyond

10:30 Morning Coffee

11:00 Exploring Direct Lytic Agents (DLAs) and their potential as a successful disruptive anti-infective technology

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

• Analysing the characteristics and benefits of DLAs against drug-resistant pathogens
• A look at the broad-based Gram-negative discovery program that optimises and develops DLA targets
• Explore the Exebacase performance as the only lysin to enter human clinical trials in the US entering phase 3
• Gain insight into the progress of the pipeline: GN Lysins and Amurins
• Evaluating the future outlook of DLA therapeutics

11:40 Candida auris: rise of a superbug

Nkechi Azie

Nkechi Azie, Vice President , Scynexis
View Bio

• Background, epidemiology and global spread
• Why Candida auris presents a significant cause for concern
• The concern for AMR and the potential utility of new antifungals such as Ibrexafungerp

12:20 Networking Lunch

13:20 The BARDA Antibacterials Program

Brian  Tse

Brian Tse, Health Scientist, Biomedical Advanced Research and Development Authority (BARDA)
View Bio

  •  Learn about the mission of ASPR and BARDA, and how it relates to the development of antibacterials
  • Find out about BARDA’s current antibiotic R&D partnerships 
  • Hear about BARDA’s contributions to the antibiotic development space 
  • Explore BARDA funding opportunities


    14:00 Immunomodulatory Therapies

    Pedro Madureira

    Pedro Madureira, CSO, Immunethep
    View Bio

    • Extracellular Bacterial GAPDH
    • Common Virulence Mechanism
    • Restore Immune system ability to control infection

    14:40 Afternoon Tea

    15:10 Panel Discussion: The development of non-traditional therapies in ID: known and unknown hurdles

    • What are non-traditional therapies?
    • Could efficacy assessments (non-clinical and clinical) used for antibiotics apply to non-traditional agents?
    • Are there alternatives to antibiotics or to be administered in combination with antibiotics?
    • What are the regulatory guidelines for the development of non-traditional therapies?
    • What is the place of non-traditional therapies in terms of financial support and regulatory designations?
    • How do non-traditional therapies address the resistance threat?

    Cara Cassino

    Cara Cassino, Chief Medical Officer, ContraFect
    View Bio

    Lorenzo Corsini

    Lorenzo Corsini, Co-Founder, CEO, Research & Development, Phagomed Biopharma GmbH
    View Bio

    Michael Dawson

    Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy Ltd
    View Bio

    16:10 Chair’s Closing Remarks and Close of Day One

    Cara Cassino

    Cara Cassino, Chief Medical Officer, ContraFect
    View Bio

    9:40 Chair's Opening Remarks

    Michael Dawson

    Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy Ltd
    View Bio

    9:50 Evaluating the utility of machine learning and AI in antibiotic drug discovery

    Paul Finn

    Paul Finn, CEO, Oxford Drug Design
    View Bio

    • Explore the applicability of machine learning and AI in accelerating antibiotic drug discovery and development
    • The technology behind the machine: proprietary 3D ElectroShape technology and the Scopius compound database
    • Case study: Aminoacyl tRNA (aaRS) Synthetase Inhibitors
    • See the opportunities and challenges that face regulator and clinician acceptance

    10:30 Morning Coffee

    11:00 Preclinical development of metallo-β-Lactamase inhibitor (ANT2681) in combination with meropenem as a potent agent against NDM-CRE

    Martin Everett

    Martin Everett, Chief Scientific Officer , Antabio

    • Worldwide CRE prevalence summary
    • Discovery of a novel MBL-inhibitor: ANT431 and reinstating susceptibility
    • Progress of the MBLi programme towards a preclinical candidate: ANT2681
    • The future of antibiotic adjuvants and combination therapies

    11:40 Discovery of Dabocins, a novel class of non-β-lactam PBP inhibitors

    Francois Moreau

    Francois Moreau, Scientific Director, Mutabilis S A
    View Bio

    • EBL-1463 is a DBO-based covalent inhibitor of Penicillin-Binding Proteins 1a, 2, 3
    • It is stable to class A, B, C, D β-lactamases, direct-acting and bactericidal against Enterobacterales
    • Overview of MIC profiles and in vivo efficacy against highly resistant MBL-producing CRE
    • Early PK/PD and human dose prediction

    12:20 Networking Lunch

    13:20 Novel Immunotherapeutics to target Gram-negative bacterial infections

    Mike  Westby

    Mike Westby, Director, Centauri Therapeutics

    • Natural antibodies and the discovery of alpha-Gal
    • Alphamer platform and how to harness the power of the immune system
    • ABX01 mechanism of action in vitro and in vivo
    • Translation of immune-recruiting agents in preclinical PK/PD

    14:00 Precision biofilm disruption and vaginome editing with phage-based technologies

    Lorenzo Corsini

    Lorenzo Corsini, Co-Founder, CEO, Research & Development, Phagomed Biopharma GmbH
    View Bio

    • PhagoMed is an Austrian pre-clinical biotech company focused on developing treatments against persistent, biofilm-associated infections. We will present two of our key assets
    • PM-398: PhagoMed’s cocktail of natural, propagating S. aureus phages could transform the standard of care in implant associated infections
    • PM-477: PhagoMed’s recombinant, Gardnerella-specific endolysin precisely edits the vaginal microbiome and is being developed for the treatment of bacterial vaginosis

    14:40 Afternoon Tea

    15:10 Inhibition of bacterial cell-wall biosynthesis by carbohydrate scaffolds targeting the glycosyltransferase activity of penicillin-binding proteins

    David Roper

    David Roper, Professor of Biochemistry and Structural Biology, University of Warwick
    View Bio

    • Penicillin binding proteins (PBPs) as excellent targets for antibacterials as exemplified by the mode of action of beta-lactams
    • Class A PBPs are responsible for the polymerisation of the peptidoglycan precursor, Lipid II into a glycan polymer required for subsequent transpeptidation crosslinking reactions by all PBPs
    • Development of a series of sugar base inhibitors of this process with promising in-vitro in-vivo properties of this Class A PBP polymerisation process
    • Exploring the mode of action providing a novel perspective on targeting bacterial cell wall biosynthesis

    15:50 Chair’s Closing Remarks and Close of Day Two

    Michael Dawson

    Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy Ltd
    View Bio


    Chief Medical Officer, Senior Subject Matter Expert
    Combioxin SA
    Health Scientist
    Biomedical Advanced Research and Development Authority (BARDA)
    Chief Medical Officer
    Consultant Clinical Adviser to NICE/Consultant Thoracic Physician & Honorary Professor of Medicine, Manchester Academic Health Sciences Centre
    Professor of Biochemistry and Structural Biology
    University of Warwick
    Microbiology Lead
    Centauri Therapeutics Ltd
    Scientific Director
    Mutabilis S A
    Co-Founder, CEO, Research & Development
    Phagomed Biopharma GmbH
    Chief Scientific Officer
    Mike Dawson Antimicrobial Research Consultancy Ltd
    Centauri Therapeutics
    Vice President
    Oxford Drug Design
    SVP Anti-infective Discovery
    Evotec Inc
    Nomad Bioscience GMBH


    Official Media Partner



    Remote UK

    United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.

    SMi's Remote Access 2020


    Speaker Interview with Martin Everett


    Speaker Interview with Paul Finn


    Speaker Interview with Emma Leire


    Speaker Interview with Michael Dawson


    Speaker Interview with Lorenzo Corsini


    Speaker Interview with Samareh Lajaunias


    Speaker Interview with Antonio Perez


    Superbugs & Superdrugs 2020 Brochure


    2020 Full Programme


    2020 Conference Speakers


    2020 Workshop Programme


    Superbugs & Superdrugs Past Attendees List


    Past Presentation 2019 - University of Liverpool


    Past Presentation 2019 - Blueberry Therapeutics


    Past Presentation 2019 - Bioharmony


    Past Presentation 2019 - GSK


    Past Presentation 2019 - World Health Organisation


    Past Presentation 2019 - Summit Therapeutics





    SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

    Media Partners

    Select Science

    Official Media Partner

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

    Global Biodefense

    Official Media Partner

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.

    Infectious Diseases Hub

    Official Media Partner

    Infectious Diseases Hub is a free-to-access website open to all researchers, students and anyone else who might have an interest in the many aspects of microbiology and virology. We offer easy access to breaking news, interviews, opinion pieces, peer-reviewed articles and multimedia features, with a strong focus on the rising issue of antimicrobial resistance. Microbiology is such a diverse and exciting area, and with the emergence of new technologies giving us the ability to study complex communities and rapidly sequence whole genomes, there has been something of a ‘revolution’. Keeping on top of such technological advances and the latest emerging diseases is at the heart of Infectious Diseases Hub, and you can take a look at up-to-date essential research and information on the site now.

    Media Partners

    Drug Discovery Today


    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    Bentham Science


    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.



    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!

    Kind Congress


    KindCongress lists scientific conferences from all over the world keeping professional conference organizers (PCO), speakers and attendees up to date with the latest conferences from a wide range of sciences. Conferences register to be seen by potential attendees and speakers. And speakers can register to get invited by conferences.

    Swiss Biotech Association


    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.



    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.



    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

    Pharmaceutical Technology


    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

    American Pharmaceutical Review


    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy



    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

    SciDoc Publishers


    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.



    Labcompare is a product of American Laboratory, and is already included in the AL logo on your website. I have attached the standalone Labcompare logo and info is below, but if you do add this one separately, could you exchange the American Lab logo with the one attached? For laboratory managers and researcher scientists across analytical chemistry and applied sciences who need to find product solutions, advice, and access scientific tools. Labcompare provides an industry-leading, comprehensive, online resource of product information to support the laboratory’s needs. Labcompare supports every step of the buying journey by focusing on core and new product technology, supplies, tips, and buyer’s guides.



    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

    Drug Target Review


    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com



    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

    Drug Development Technology


    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.



    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

    International Pharmaceutical Industry


    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.



    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Remote UK

    United Kingdom

    Remote UK



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out